• Calling POAI undervalued, Litchfield initiates coverage of Predictive Oncology with Buy rating, $3 price target
• The drug industry is changing as tools and technology to tailor drugs emerge, regulatory bodies focus on patients’ experiences, perspectives, needs
• Litchfield report notes several POAI strengths under “Investment Thesis” section

A growing number of companies and health providers alike are paying attention to what the FDA is calling patient-focused drug development (“PFDD”), a systematic approach to help ensure that patients’ experiences, perspectives, needs and priorities are captured and meaningfully incorporated into drug development and evaluation. In that growing market, Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has been given a “Buy” rating by equity research firm Litchfield Hills Research LLC, which uses a three-tiered (buy-hold-sell) rating system (https://ibn.fm/lMp50).

“If you have ever had a medical condition that had to be treated with medication that had complex dosing requirements or complex directions for taking the medication, or side effects that made you stop, the drug industry is now paying attention,” noted Litchfield’s first analyst coverage report on Predictive Oncology. “Development of drugs to treat diseases was never tailored to any one individual because the tools to do that weren’t available, so development was generally not optimized for individual patient outcomes in terms of Active Pharmaceutical Ingredients (‘API’), side effects, getting the most out of the least amount of API (bioavailability), and medication regimen complexity and adherence.

“However, that is changing, especially as tools and technology to tailor drugs emerge, and the regulatory bodies, like the FDA, are focused on patient’s experiences, perspectives and needs,” the Litchfield report continued. “As experts in what it is like to live with their condition, patients are uniquely positioned to inform the understanding of the therapeutic context for drug development and evaluation.”

The report notes several of POAI’s strengths under its “Investment Thesis” section, including that the company is “advancing state-of-the-art patient-centric drug development systems, which is the leading edge of current drug development, as the industry tries to reduce the time needed for commercial drug development.” Other strengths include that the company operates four subsidiaries, that its commercial business provides a stable revenue stream, and that the company has a strong balance sheet, having just completed a capital raise. In addition, the report notes that POAI has an “exceptional management team. The company has assembled an experienced management team for each of its pre-commercial subsidiaries to advance them towards commercialization.”

Calling POAI undervalued, Litchfield pronounced the following: “We are initiating coverage of Predictive Oncology Inc. with a Buy rating and a $3.00 price target. Predictive Oncology Inc. (NASDAQ: POAI) is a commercial stage biotech firm tackling cancer, assisting in vaccine development and solving medical waste issues.”

Litchfield Hills Research adheres to FINRA standards for quality and objectivity. The Litchfield Hills Research Department certifies its report is compliant with FINRA research rules 2241, 3110; that Litchfield is registered with FINRA; and that the report has been reviewed by a supervisory senior analyst. Litchfield’s price target, financial models, peer comparisons and investment thesis are developed without input from management of the company, and it performs its own due diligence.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• With Mediscan, the option of having scanning equipment at patient’s location is becoming increasingly viable
• Patent-pending Mediscan software converts ultrasound analog 2D grayscale image into digital 3D HD format
• Software can generate quality 3D medical images of broad variety of organs, including heart, lungs, tendons, skin and nerves

Since its introduction into the world of medicine, the ultrasound has become one of the most efficient, reliable ways to examine the human body in a noninvasive way. And now, this medical mainstay has become even more essential in providing quality care — proprietary technology from Healthtech Solutions (OTC: HLTT) subsidiary Mediscan Inc. can transform traditional 2D images from a portable ultrasound machine into invaluable 3D images to provide even more accurate internal views and, consequently, better diagnosis and health care. “Ultrasounds give an accurate image of body parts in the least amount of time, and even allow the patient to experience real-time results,” reported a recent Mediscan blog. “In fact, [ultrasounds] can produce a high-definition image in less than ten seconds.” That turnaround time is impressive, especially when compared to technologies such as CTs and MRIs, which can take anywhere from 24 hours to an entire week before results are available. The speed of ultrasounds becomes even more critical during emergencies, when the ability to have point-of-care ultrasound (“POCUS”) can save lives. Thanks to Mediscan, the option of having scanning equipment at a patient’s location — whether that is in an ambulance, at an assisted-living facility or even at a patient’s own home — is becoming increasingly viable. Fundamentally, the Mediscan software converts an ultrasound analog 2D grayscale image into a digital 3D HD format. This transformation can take place in traditional ultrasound locations; the Mediscan application integrates with all popular EMR systems. In addition, because the software is designed to pair with portable ultrasound machines, it can be used in less traditional settings. The exclusive software can provide valuable insight to on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (“EMS”) personnel, and technicians in isolation wards and emergency rooms. The process is simple. This patent-pending, cloud-based software application for ultrasound devices is easy to use wherever the internet is available. Once an image has been captured in 2D, it is converted using a cloud-based software application process. The now-3D image can be viewed on a computer monitor, pad or smartphone at the point of service, providing the convenience of point-of-care ultrasound with the image quality of CT or X-ray and the safety of expensive MRI technology. The software can generate quality 3D medical images of a broad variety of organs, including the heart, lungs, tendons, skin and nerves. Healthtech Solutions, through its subsidiary Mediscan Inc., offers technology that can transform 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The technology has multiple applications in lung, cardiac and musculoskeletal imaging and related uses. For more information, visit the company’s website at www.MyMediScan.com. NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

• The COVID-19 pandemic is a year old, having devastated a number of markets since its discovery and spread were first reported in China
• While many industries have suffered worldwide during the year, the distancing requirements instituted in response to the pandemic have led buyers to turn to online retail outlets for many products
• Consumer products marketer Mohawk Group Holdings has been ideally situated to take advantage of the 44 percent growth in online commerce spending during 2020 and beyond
• Mohawk’s stock took an initial beating with the outbreak of the pandemic, but has since rebounded and rose more than 400 percent during the past three months alone
• The company’s holdings saw sales grow from $88.8 million to $144.2 million during the first nine months of 2020

Consumer products platform Mohawk Group Holdings (NASDAQ: MWK)  is riding a wave of optimism as an online retail marketer benefitting from the spike in remote access purchasing during the year-old COVID-19 pandemic. Mohawk principally leverages its proprietary technology as a third-party seller on Amazon, and grew sales revenue from $88.8 million to $144.2 million during the first nine months of 2020 reported in its most recent quarterly filing (https://ibn.fm/TyCKQ). An outside market opinion writer published this month in media outlet The Motley Fool noted that the company’s shares took a huge dive when the pandemic provoked strict commerce-limiting measures throughout the United States last year, but has also sharply rebounded. “Yes, the stock is up over 400% in the past three months, but it is still early innings for this tech-enabled CPG (consumer packaged goods) conglomerate, so don’t fool yourself into thinking you’ve missed the boat with this business,” the opinion writer, Brett Schafer, states (https://ibn.fm/yV8Jc). Schafer cited a Digital Commerce 360 report stating that e-commerce has experienced tremendous growth during the past year, with online shopping forming more than 20 percent of retail spending in the United States during 2020. The $861 billion spent online was a 44 percent increase over the previous year. Amazon captured nearly a third of the online market share, with sales growth of 54 percent during the final quarter of the year. Mohawk’s position as a third-party Amazon seller allows it to ride the commerce giant’s coattails. The company’s Artificial Intelligence Mohawk E-commerce Engine (“AIMEE”) helps it identify market opportunities then design, develop and launch products from its stable of 12 brands in categories including kitchenware and home appliances, environmental appliances, beauty products and consumer electronics. Mohawk also sells its AIMEE software to other online sellers, granting the company revenue with high margins and a huge market opportunity. The company has offices in the United States, Canada, China and the Philippines and takes advantage of its global footprint to move its products around the clock. The platform’s Fulfillment Engine helps to guide inventory location, cost optimization and use of third-party networks to cut shipping times. When Mohawk announced the acquisition of online essential oils seller Healing Solutions, LLC in early February, the company reported it expects the acquisition to help boost its net revenues for 2021 to a range between $340 million to $370 million, with net income for the year estimated to reach between $1 million and $5 million primarily in response to quarterly interest expense, net and stock-based compensation expense. Mohawk forecasts its adjusted EBITDA will be between $28 million and $32 million. For more information, visit the company’s website at www.Mohawkgp.com. NOTE TO INVESTORS: The latest news and updates relating to MWK are available in the company’s newsroom at https://ibn.fm/MWK

• Imagin Medical Inc.’s patented i/Blue System revolutionizes the way surgeons are able to visualize the bladder and identify cancers during surgery
• The breakthrough technology of Imagin Medical’s i/Blue Imaging System rectifies the limitations of both white and blue light cystoscopies
• Bladder cystoscopies first target – multiple other endoscopic procedures planned

Science and technology have continued to make striking advancements in cancer therapeutics and treatment protocols, improving upon on past successes and creating better outcomes for cancer patients. A prime example is an exciting new development in visualizing cancer during minimally invasive surgeries. Surgical imaging company Imagin Medical (CSE: IME) (OTCQB: IMEXF), is establishing a new paradigm in a doctor’s ability to “see” and surgically treat cancers. With bladder cancer as its first target, Imagin Medical’s initial product is the i/Blue Imaging™ System. The company’s patented, ultrasensitive imaging technology is based on advanced optics and light sensors and employs ultrasensitive imaging technology. Identifying potential early-stage tumors can be difficult because of the inability to distinguish between healthy tissue and tumors when viewed through a scope only using conventional white light. Cystoscopy is the conventional diagnostic procedure for visualizing bladder cancer during surgery. It allows the doctor to see inside the body with a thin, lighted, flexible tube called a cystoscope which uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Like a roadmap with street signs, white light images show the full landscape of the bladder but do not effectively highlight cancer. A promising new modality, blue light cystoscopy, uses blue-filtered white light to detect flat tumors and cancerous cells not seen with white light that may be left behind during surgical removal of the tumor. However, surgeons can’t operate using blue light images. The blue images aren’t in real time, orientation in the bladder is easily lost and the surgeon must manually switch from white to blue cystoscopy and back again. Both white and blue light cystoscopies have effective uses and serious limitations in seeing the landscape of the bladder and identifying all the cancerous cells during surgery. Missing any cancerous cells poses serious concerns because they will continue to grow and spread to other parts of the bladder, a fact reflected by the recurrence rate of fifty per cent. The breakthrough technology of Imagin Medical’s i/Blue Imaging System rectifies the limitations of both white and blue light cystoscopies. By combining the white and blue light with an FDA-approved imaging agent, the i/Blue System displays side-by-side images in real-time, without the necessity to switch back and forth between the two images. Unlike any other modalities on the market today, Imagin Medical’s i/Blue Imaging System can attach to almost any endoscope model currently in use which creates a plug and play state-of-the-art system adaptable to virtually any clinical setting. Imagin Medical is advancing the i/Blue Imaging System toward commercialization. The FDA approval process is underway, and the company’s intellectual property is well-protected. Perhaps even more significant, Imagin intends to build on the i/Blue technology which will facilitate entry into multiple other endoscopic procedures. Imagin Medical is improving on past technologies and creating better outcomes for patients while even at a reduced cost. For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Industry’s rapid growth paired with affiliates, loyalty and gaming programs creates higher retention
• Cryptocurrency making future of online gaming secure
• Plans to go public on exchanges in Canada, UK, Europe, and the U.S.

Mobius Interactive’s co-founder and COO Robin Lawson was recently interviewed by G&M News, a global source of gaming information (https://ibn.fm/2pHJo). Specializing in Esports, sports betting, casino and live casino, Mobius is excited about the future of the industry in 2021 and beyond. Lawson discussed the company’s rapid growth, how blockchain impacts the gaming industry and future plans for the company. In September 2020, Mobius launched three brands: Mobius Bet, Aragon Casino and Club Double. Combining these brands with an affiliate platform and a full loyalty program has brought Mobius early success. The company will soon be implementing a gamification program to further empower the brands and succeed in the marketplaces they are entering. Through the affiliate program, Mobius has partnered with more than 600 VIP and master gamers. These affiliates introduce high-value players to the company’s iGaming platform. Those gamers are then provided a personalized gaming experience through the company’s real-time CRM system. Rather than focus wholly on acquisition, the company is using the loyalty and gamification programs to increase engagement. These programs have been shown to increase daily wagering up to 30% while also increasing daily player activity by 60%. Lawson went on to discuss significant changes in the online gaming community, from unprecedented growth during 2020 due to the pandemic and lockdowns to the use of blockchain and Bitcoin in the gaming industry. “We are seeing improved payments on betting with cryptocurrencies like Bitcoin, which is one of a number of crypto depositing options we offer on all of our Mobius Interactive brands,” stated Lawson. “Crypto is becoming more trusted globally. In fact, it is competing with gold right now, so I think it’s very safe to say the future for our industry is incredibly bright and we have a lot of exciting new technologies to look forward to in this field.” Over the next two years, Mobius has plans to consolidate the brands in all the regions the company enters as well as go public on exchanges such as Canada, UK, Europe and the United States. For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• Autonomous security robot (“ASR”) developer Knightscope is experiencing a marked growth in investment interest through its Reg A+ offering, now counting more than 20,000 private financial backers
• CEO William Santana Li told interviewer IPO Edge the company has a plan to eventually go public, but continues to value the backing of police officers, federal law enforcement officers, corporate security officers and investment bankers with skin in the game
• The ASRs utilize artificial intelligence to monitor client properties and machine learning tools to successfully navigate during their patrols, with indoor and outdoor models available
• Knightscope’s ASRs help minimize risks to human personnel of physical harm, tedium and infection during the ongoing pandemic

Security robot manufacturer Knightscope rolled out its first autonomous product in 2015 and has watched its fanbase steadily grow during the years since then, topping 20,000 investors in February following a quick burst of new energy on the public involvement front.

During a virtual fireside interview with IPO Edge in December (when Knightscope was still reporting investors at the 17,000 level), CEO William Santana Li explained the importance of the company’s Reg A+ offering that allows Knightscope to attract private investments between $500 and $10 million online without launching a public IPO, although the company maintains a plan to go public eventually (https://ibn.fm/GsMB1). You can read about what the Company can legally say at this time about a public listing here.

“Do you know who our investors are? NYPD detectives, FBI, CIA, DHS, investment bankers, recruiters, great legal minds, chief security officers of major corporations, vice presidents of leasing of major malls and REITs. … They’re financially motivated to help the company,” Li said.

“Folks that look at this and they’re like, ‘Ah, you did this equity crowdfunding type of stuff,’ like in a negative type of way. And I’m like, ‘You know, what do you think Goldman Sachs and Morgan Stanley do all day? Someone files an S1 and what is that? That is one massive global equity crowdfunding exercise to get every Tom, Dick and Harry to write a check,” Li added. “If you look at the mission, you’re trying to secure the entire U.S. and you’re serious about it, do you really think four VCs sitting in a room, worried about all the wrong things, is how you’re going to change the world? You’re going to have to do this piece by piece and you’re going to need a lot of support.”

Knightscope’s strategy is to deliver autonomous security robots (“ASRs”) that harness A.I. developments, giving them the capacity to monitor broadcasts, thermal signatures and physical surroundings in 360-degree environments while recording what they detect and reporting it back to a monitoring center.

The company promotes its sentries’ ability to patrol facilities indoors and outdoors on a 24/7 basis 365 days a year, removing humans from front-line interactions until it’s necessary for them to intervene and thereby minimizing some of the hazards arising from armed confrontations, tedium and contagion during the currently ongoing pandemic.

Li acknowledged that there have been hurdles to overcome along the way and that everything has not gone perfectly, but also noted that the company’s robots have been popular enough that clients often have naming ceremonies to welcome the newest robotic members of their personnel teams and that members of the public have sometimes been known to hug or kiss them.

“Henry Ford (the founder of the Ford Motor Company and chief developer of the assembly line that drove mass production techniques) once stated, ‘If I had asked people what they wanted, they would have said faster horses.’ Sometimes you just have to create something all new that’s never been done before,” Li says in an investor relations video on the company’s website (https://ibn.fm/ZWM5b). “We’re blazing that new trail in law enforcement, physical security and public safety.”

The company’s robots are operating across the country’s five continental time zones, and Li noted in the fireside interview that the company has arrived at a point in its history where “every issue that we’ve got in the building we can fix with people, cash and time.” While some competitors have arisen over the years and more may yet arise, Li said, “At this point, I think we’re the worldwide leader and hope to maintain that leadership.”

For more information, visit the company’s website at www.Knightscope.com.

Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO.

DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Company announced discovery of high-grade silver mineralization at Grauer Wolf target
• Excellon continues to develop and test new targets along the 36-kilometer strike length
• EXN advancing a precious metals growth pipeline in Idaho, Mexico and Germany

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2), a silver and base metals producer with operations in Mexico and precious metal exploration projects in Mexico, Idaho and Germany, has announced a new discovery. The discovery of high-grade silver mineralization comes at Grauer Wolf, the fourth target drilled at EXN’s Silver City project (https://ibn.fm/1vKtG). According to the announcement, the discovery is located on a geological site with little historical mining and adds a fourth priority area for follow-up in the 2021 drilling program at Silver City. With eight holes still outstanding, there is strong potential for additional discoveries in parallel strikes. The company is in the process of planning and preparing for more extensive drilling for its Bräunsdorf, Reichenbach, Peter Vein and now Grauer Wolf projects. Excellon is focused on advancing a precious metals growth pipeline through exploration and development of projects that include:

• Platosa — 11,000 hectares hosting the highest-grade silver mine in Mexico and 100% owned by EXN (https://ibn.fm/vCZjs)
• Kilgore — 6,788 hectare high-quality gold development project in Idaho and 100% owned by EXN (https://ibn.fm/StydP)
• Silver City — high-grade epithermal silver district in Saxony, Germany with the option to own 100% (https://ibn.fm/N8Jm9)

The 16,400-hectare Silver City project has been mined for 750 years. Records indicate high-grade silver production in excess of 1,000 g/t was mined throughout the area. Mining slowed to a standstill in the late-19th century after Germany dropped the silver standard in 1873 and the gold/silver ratio skyrocketed when silver prices plummeted. EXN is the first modern-day exploration program to focus on precious metals throughout the area, and the company is already seeing promising results. Thanks to this new discovery, Grauer Wolf is now the fourth priority area for follow-up in the Silver City 2021 drilling program. Lesser known and located 1.5 kilometers north of the Reichenbach target, Grauer Wolf is a relatively unexploited mafiac volcanic contact. EXN continues to develop and test new targets along the Silver City Project, a 36-kilometer strike length on the Bräunsdorf license that historical records indicate has produced at least 882 tonnes of silver as well as zinc and lead (https://ibn.fm/dfDzR). Many of the vein systems under this license have only been mined at shallow depths leaving the potential for many new discoveries. Excellon’s vision is to create wealth by realizing strategic opportunities through discipline and innovation for the benefit of its employees, communities and shareholders. The company also aims to continue capitalizing on current market conditions by acquiring undervalued projects. For more information, visit the company’s website at www.ExcellonResources.com. NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at https://ibn.fm/EXN

• UEC president CEO Amir Adnani is featured on a recent episode of Bell2Bell Podcast.
• Adnani notes that Uranium Energy Corp. is focused on rebuilding, restarting a domestic infrastructure to mine uranium for carbon-free nuclear energy.
• The Company’s production area in the Burke Hollow project is the newest, largest ISR well field being developed in the country.

Uranium Energy (NYSE American: UEC) president and CEO Amir Adnani was featured on a recent episode of The Bell2Bell Podcast (https://ibn.fm/6mYtD), a podcast series focused on providing informative updates and exclusive interviews with executives leading companies that are operating in fast-moving industries. Under Adnani’s guidance, Uranium Energy advanced from concept to U.S. production in its first five years of operation; UEC currently has an extensive pipeline of low-cost, near-term production projects.

“Uranium Energy Corp. is a U.S.-focused developer of uranium projects using the low-cost and environmentally friendly in-situ recovery (‘ISR’) method,” said Adnani during the podcast as he provided an overview of the company’s business model. “In South Texas, we have our hub and spoke strategy. This is anchored by our fully licensed Hobson Processing Facility, one of only a few uranium processing plants in the country. We have a number of projects . . . which will be a source of U.S.-mined uranium.”

In addition to discussing the company’s business model, Adnani touched on recent company news, specifically talking about the company’s plans moving forward as the United States looks to decrease its reliance on carbon-based fuels. “Uranium is used for generating electricity in nuclear power plants, and 55% of U.S. carbon-free energy comes from nuclear power,” he said, noting that almost all of the uranium currently needed in the country to fuel reactors is coming from foreign sources.

“We have completely lost the ability to mine uranium in the U.S. from domestic sources,” he continued. “You and I both know the importance of local sources of vital needs, be it energy sources, be it masks, be it pharmaceuticals. So what we’re trying to do is to really rebuild and restart the domestic foundation to mine uranium — the fuel that is needed to run our 94 reactors in this country.”

During the interview, Adnani talked about the federal government’s bipartisan support of a U.S. Uranium Reserve and the allocation of funds to purchase uranium produced by U.S. mines, noting that he’d never seen such a move in his extensive experience in the industry. “[UEC] is getting ready to supply uranium to the global market and this new U.S. reserve,” he noted, pointing to the company’s Burke Hollow project, located in Texas. Burke Hollow’s initial production area is the newest and largest ISR well field being developed in the country (https://ibn.fm/6Br4k).

“We need to have a foundation to mine uranium domestically in the United States,” Adnani stated. “We’re rising to that occasion as a company. As a company we are today, at our Burke Hollow project… currently building one of the largest production areas currently in the United States…We have rigs on the property, we’ve got local staff, our team. We’re hiring locally. We’re creating jobs and adding to the economic development of the local communities that we’re in, in Texas…These are incredible opportunities, because not only are we creating local jobs…we’re also tying it back to developing the ability to mine uranium domestically. And again, this dovetails strategically with our plans to be a key supplier to the U.S Uranium Reserve.”

Adnani also talked about the strength of the company’s portfolio, which includes projects in Texas, Wyoming, New Mexico, Colorado and Arizona, as well as Canada and Paraguay, noting that the company looks to be ideally positioned as the market looks to expand and grow.

Uranium Energy Corp. is a U.S.-based uranium mining and exploration company that controls one of the country’s largest historical uranium exploration and development databases. Founded in 2003, UEC is headquartered in Corpus Christi, Texas.

For more information, visit the company’s website at www.UraniumEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at https://ibn.fm/UEC

• Studies confirm natural active ingredient, which is in MustGrow’s biopesticide, has a positive impact on soil health
• Soil micro-organisms play crucial role in soil fertility, plant health
• MustGrow’s safe, effective natural biopesticide is plant based, derived from the mustard seed’s natural defense mechanism

MustGrow Biologics (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) has released study findings that confirm that the active ingredient in its mustard plant-based technology actually has a positive impact on soil health (https://ibn.fm/uLwuc). The studies have found that an application of the natural ingredient Allyl Isothiocyanate (“AITC”) returns organic plant material to the soil and contributes to the environmental and ecological security of the plant-based food supply as well as the planet generally.

“The active ingredient, AITC, in MustGrow’s mustard plant-based technology is perfect for use in modern, more sustainable pest control strategies,” said MustGrow scientific advisor Dr. Matthew J. Morra. “A biopesticide that is effective, dissipates quickly, leaves no harmful residues, and once gone, improves the soil ecosystem.” A professor emeritus of soil biochemistry at the University of Idaho, Morra is a leading world expert on products derived from oilseeds; he also has impressive expertise in developing mustard-based biopesticides.

Highlights from the study, which was separate from MustGrow, indicate that an application of AITC returns organic plant material to the soil, improves the environmental and ecological security of the planet, and creates a healthy microbial ecological environment for soil, which increases beneficial bacteria. In addition, AITC dissipates from the soil quickly, thereby eliminating any potential long-term toxicity to microorganisms.

The potential impact of MustGrow’s biopesticide on the soil cannot be overlooked. Soil micro-organisms play a crucial role in soil fertility and plant health. The use of synthetic chemicals in soil fumigation has been proven to harm beneficial micro-organisms, fungi and bacteria in the soil, actually creating a negative impact on soil fertility, plant health and nutrient transformation. So the now-verified positive impact that AITC has on soil is significant. Studies and research done on AITC have consistently concluded that the ingredient has a positive effect on the environmental and ecological security of the planet.

MustGrow’s remarkably safe and effective natural biopesticide is plant based, derived from the mustard seed’s natural defense mechanism to control diseases, pests and weeds with an organic food-grade biopesticide. The product is applied to the soil before seeds are planted. There is a growing interest in safe, effective, and plant-based biopesticides as farmers, consumers and investors alike become more aware of and committed to natural alternatives to synthetic chemical pesticides.

An agriculture biotech company, MustGrow is focused on providing natural, science-based biological solutions for high-value crops such as fruits and vegetables. The company is ideally positioned to leverage the growing momentum favoring alternatives to synthetic chemicals. As global agriculture looks to move closer to sustainable ways of boosting yields and crop protection, MustGrow continues to position itself as an essential part of the food landscape of the future with its mustard plant-based biopesticide.

For more information, visit the company’s website at www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

• Pure Extracts is preparing to deliver shipment of 85% pure CBD distillate
• Company proud of quality offering produced in world-class facility
• PULL uses proprietary state-of-the art, sub-critical/super-critical CO₂extraction system

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company, has signed a contract for its first CBD oil commercial sale on the wholesale market (https://ibn.fm/92kPG). Pure Extracts is preparing to deliver the first of what it anticipates will be multiple shipments this year of its 85% pure CBD distillate under this contract. “We are excited to have completed our first commercial order, and we are proud of the quality of distillate that our extraction team has produced in our new, world-class facility,” said Pure Extracts CEO Ben Nikolaevsky. According to a recent update, Pure Extracts finished construction of its state-of-the-art facility last year (https://ibn.fm/B65HW). Located about 20 minutes north of Whistler, British Columbia, the center is built to European Union GMP standards and is the perfect complement to Pure Extracts’ Standard Processing License, which the company received from Health Canada on September 25, 2020 through its wholly owned subsidiary, Pure Extracts Manufacturing Corp. Pure Extracts is gaining a reputation for providing exceptionally pure THC and CBD full spectrum oil (“FSO”) and distillate. The company obtains such a high-quality offering by using its proprietary state-of-the art, sub-critical/super-critical CO₂ extraction system. The distillate is ideally suited for use in most cannabis 2.0 products, including beverages, edibles and vape pens. With such a high-quality product available, it is perhaps no surprise that the company is seeing success in the toll processing and white labeling space. Pure Extract offers the ideal solutions for LPs that lack the extraction expertise and requisite equipment to manufacture their own raw materials. In addition, Pure Extracts is also developing its own private label of products; the Pure Pulls and Pure Chews brand, which will include vape pens and edibles, will incorporate the company’s own full spectrum THC and CBD-based extracted oils. In conjunction with the company’s commitment to strengthen its brand awareness and expand into new spaces, Pure Extracts is teaming up with Native Ads Inc. and Winning Media to create and execute digital advertising campaigns. Under the terms of the agreement, Native Ads and Winning Media will provide strategic digital media services, marketing coordination, content production and data analytics services — all designed to support Pure Extracts as it moves forward with its strategic growth and expansion plans. Pure Extracts Technologies Inc., headquartered in Pemberton, British Columbia, is a plant-based extraction company with a new vertical in functional mushrooms with plans the enter burgeoning psychedelic mushroom sector once it receives a Dealer’s Licence from Health Canada. A Dealer’s Licence would allow the company to handle, manufacture and sell substances such as psilocybin and psilocin. The company is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL